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I 
 
Abstract 
 
Nanomedicine, the nanotechnology for development of efficient and safe medicines affects to 
biotechnology and chemistry during several decades.1,2 The interest in nanomedicine offers the 
innovation of drug delivery system using nanoparticle.3 The advantages of nanoparticles in the 
therapeutic application includes following properties. First, they can enhance the effect of medicines 
without displace other drug molecules for pharmacokinetic effects. Second, the specificity to the 
diseased cell by targeting delivery showed efficiency than chemotherapy. Third, they can across the 
primary barrier to the immunological response. Nowadays, the modifiable drug carrier performs 
multimodal delivery with the imaging agent and therapeutic reagent. They can pack diverse cargo 
molecules such as proteins, peptides, genes, sugar as well as a variety of chemical reagents. Especially, 
the targeting ability of nanoparticle system has attractive property to development. Passive targeting is 
one kind of focusing mechanism of nanoparticle. The nanoparticle can be accumulated in the active 
site in targeting site with cell population.4 Active targeting is the other way for targeting method of 
nanoparticle. The key to this method is surface modification. Conjugation with affinity ligands 
provides the unique binding ability with disease tissues and cells. Through past 30 years, there were 
quite a number of nanoparticle models developed for the therapeutic purpose. However, only a very 
few of nanoparticles applied in clinical development and none of them have been used for clinical 
purpose.5,6 The lack of understanding phenomenon inside cellular level with nanoparticle and 
reproduction problem for synthesis nanoparticle hampers the clinical translation.  
  In this thesis, we treated several researches trying to solve current problems in drug delivery area. 
First, the study of investigating of cargo release mechanism using polymeric micelles would give us 
the useful solution for developing future theragnostic nanoparticle. We used well-known polymeric 
micelle system which includes biocompatibility and resistance to cytotoxicity. Clear understanding of 
a cellular pathway for release drug molecules will open the gate for clinical application. Second, we 
developed the natural polypeptide based supramolecular nanogels for resolve current premature 
release problems. The biocompatible nanoparticle including the ability regarding triggered release will 
give us the other possibility using natural polypeptide as the material for nanogel system. Lastly, the 
nanoparticle models with unique targeting ability are developed following the current trend of this 
research area. Their particular advantage for affinity and targeting subcellular organelles provides 
more efficient way for cure disease through nanoparticle systems. 
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Chapter 1. Introduction 
 
1.1 Nanoparticles for Cancer Therapy  
 
In the therapeutic area, nanoparticle means the nanoscale particles are consisted of the cargo 
molecules and carrier molecules. The carrier molecules make a complex or form self-assembled 
structure with small drug molecules, genetic components, proteins and peptides. The cargo molecules 
inside of nanoparticle perform their unique role to cure disease after release from nanoparticle. Drug 
delivery system, as a detour for pharmacokinetic effects generally use nanoparticle due to these 
properties. Furthermore, the nanoparticles can be modified their functional activity by conjugation 
with targeting molecules.  
The size of the nanoparticle distributed from 10 to 100 nm. They can be eliminated by renal 
clearance in 10 nm scale.7 Furthermore, the enhanced permeability and retention effect (EPR) can be 
applied to 100nm scale of nanoparticles. The growth rate of tumor cells is exceptionally fast than that 
of typical cell. Because of this abnormal growth, the tumor cells compose leaky tumor tissues. For this 
reason, the macromolecules can be leaked from blood vessels and then accumulated in tumors.8 
Therefore, well-designed nanoparticles with a slight charge can be utilized for tumor therapy.  
 
 
Figure 1.1 Schematic representation of Enhanced Permeability and Retention (EPR) effect 9 
2 
 
Based on this mechanism, the nanoparticles were developed during previous 40 years. Liposomes, 
polymeric macromolecule system, and dendrimers were used as candidates for carrier molecules. 
Doxorubicine encapsulated liposomes (DOXIL) is already approved by FDA for nanomedicine.10 
Genoxol-PM11, the polymeric nanoparticle including paclitaxel also already utilized for therapeutic 
purpose. However, the number of nanoparticles in clinical development is too small comparing 
number of researches in nanomedicine. Design an efficient system with practical feasibility is needed 
to introduce nanomedicine on the ground.  
 
 
Figure 1.2 Time line of clinical stage nanomedicine12  
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1.2 Polymeric Nanoparticles  
 
Block copolymers, as a promising candidate in the therapeutic application, provides versatile 
chemical modification with controlling size and shape in the solution. This material forms macro scale 
molecular structure because of the nature of the hydrophobic part. In the water, the low critical 
aggregation concentration and slow interchain exchange are the strong point of the biological 
application.13 The phenomenon called as self-assembly provides a simple and tunable method for 
creating a variety of well-defined nanostructures. In case of polymeric nanostructures took attention in 
drug delivery field as well as cosmetics, nanoreactor and sensors.14,15 
The attention to polymer as the potential material for drug delivery system was started from 
1960’s.16 In 1970’s, the biodegradable polymers for controlled release change the flow of polymer 
researches by introducing these materials for therapeutic purpose. Nowadays, there are several 
polymers for controlled release. They include poly(D,L-lactide-co-glycolide), poly(lactic acid), 
poly(glutamic acid), and poly(caprolactone).17 Especially, PLGA, PLA have been generally used due 
to their biodegradable properties. Furthermore, they can be removed from the body by simple 
clearance procedure.18 The numerous researches using polymeric macromolecules were developed for 
improving drug efficacy, reduce side effects, and longer circulation in the body.19 Up to 1990’s, the 
efforts of these researches showed the result as successful clinical application. 
Different from the liposome nanoparticle system, it gives us the solution regarding premature 
release problem with their stability. For this property, we can reduce off-targeting effect in cancer 
therapy by using polymeric micelles. Furthermore, it has compatibility to various reagents with 
loading high amount of drug molecules. Small limitation of cargo loading amount also gives us 
driving force to development of polymeric carrier system. Enhanced targeting ability by surface 
modification, controlled release and triggered release of cargo molecule are the other advantages of 
polymeric micelle.20   
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1.3 Active Targeted Nanoparticles  
 
Active targeted nanoparticles efficiently deliver their cargoes to target cell.21 After internalization 
through diverse endocytosis pathways, the hydrophobic drugs readily permeate to endosomal 
membrane via lipid bilayers. After internalized endosome, the released drugs permeate intracellular 
spaces. Through several studies, ligand mediated endocytosis showed enhanced cell internalization 
ability than non-targeted nanoparticles.22,23 The research comparing targeted nanoparticles and non-
targeted nanoparticles demonstrated the effect of targeting ligand as enhanced cellular uptake to target 
cells.23 In the targeted nanoparticles, the nanocarriers provide colloidal properties with a 
biodistribution. In case of targeting ligand, they serve efficient and facile endocellular uptake at the 
target sites.24 
Most of nanoparticles for active targeting are prepared by direct conjugation of affinity ligands. 
Antigen as one kind of affinity ligand is overexpressed on the plasma membrane. They are also 
overexpressed in the diseased tissue. The first introduce of antibody to nanoparticle was performed in 
1980’s. In that report, the monoclonal antibodies were modified on the surface of liposome to 
recognize antigens on target cells.25 Up to date, there were 30 monoclonal antibodies applied for 
clinical use. For example, the monoclonal antibody rituximab was approved for non-Hodgkin’s 
lymphoma. Humanized monoclonal antibody trastuzumab have the affinity to HER2/neu antigen. 
That also applied to treating breast cancer.26 In nanomedicine, their affinity proteins specific active 
targeting ability was utilized to nanoparticle.27 The ligands were conjugated to the surface of 
nanoparticles carrying diverse molecules at once as well as delivering higher amount of drug 
molecules.  
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1.4 Mitochondrial Drug Delivery System  
 
Mitochondria performs several physiological regulations regarding cell living such as inducing 
apoptosis, calcium storage, and electron transfer.28 Diabetes, cancer, several mitochondrial diseases 
are caused by malfunction of energy transfer system, fail of apoptosis regulation and mutation of 
mitochondrial DNA.29-30 Due to these reasons, the studies in this field have concentrated on the 
primary mechanism of mitochondrial diseases. However, delivering small molecules including 
coenzymes for electron transfer, antioxidants, mitochondrial proteins and mitochondrial DNA is 
needed to cure mitochondrial disease. In this field, lack of researches regarding mitochondrial 
targeting drug delivery system is a big hurdle for construct delivery systems. To realize mitochondrial-
delivery system for mitochondrial disease, investigating the mechanism of mitochondrial disease has 
to be accompanied with primary level.31  
The ideal model for mitochondrial drug delivery system includes following issues. First, it must be 
effective drug carrier with simple packaging methods. Second, the delivering carriers must have the 
targeting ability of specific cells. Lastly, the trafficking as intracellular level also considered before 
reaching mitochondria. To make perfect mitochondrial-targeting delivery vehicle, the device have to 
regulate intracellular trafficking and deliver their cargo molecule to the exact site with appropriate 
timing.  
There are several candidates for targeting ligands to achieve targeting mitochondria. Especially, 
utilizing lipophilic cation is the reliable method for penetrating lipid bilayer of mitochondria. In living 
cells, the mitochondrial membrane has potential about 130 to 150 mV due to ATP reproduction. 32 The 
lipophilic cation can pass the hydrophobic barrier of mitochondrial membrane due to their positive 
charge.33 That is because of the mitochondria accumulates lipophilic cation on the surface of 
mitochondrial membrane. This approach has been selected for cancer therapy through mitochondrial 
targeting. The higher distribution of mitochondria in cancer cells provides selectivity with lipophilic 
cations.34 However, the cytotoxicity from cationic charge and nonspecific interaction with 
mitochondria in normal cell remained as assignment.  
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Chapter 2. Synthesis of PEO-b-PLA Block Copolymer for Controlling 
Encapsulation Stability 
 
2.1 Introduction & Background 
 
Polymeric Micelles for Drug Delivery System  
 
Decades of fundamental studies provide a foundation for understanding self-assembled 
morphologies. Especially, polymeric nanostructures are applied to diverse nanotechnology due to their 
assemblies in the solution. In drug delivery system, self-assembly provides the key to beyond 
aggregation problem among small molecules. Under careful preparation, the amphiphile polymers 
forms kinetically entrapped structure because of their slow dynamic process.35 The general 
preparation methods employ cosolvent mixtures that reflect the morphologies from equilibrium 
thermodynamics. The various structures such as spherical micelles, cylindrical micelles and vesicles 
can be emerged from same methods by following their kinetics.36,37 It is important to select adequate 
solvent for increasing energy barrier to getting kinetically entrapped structures. The principle of 
cosolvent processing is applied to therapeutic agents. The mechanism enables to loading hydrophobic 
molecules in the micelle structure.38  
By following this method, the general phenomenon showed the result as maintenance of 
macromolecular structure.39 People told the phenomenon as ‘stable’. This means most of studies 
regarding polymeric micelles are performed under assumption of their forming mechanism. As long 
as the primary mechanism remains as unclear, we cannot control the stability issues for polymeric 
micelle system in drug delivery research. Currently, there are two perceptions to forming polymeric 
micelle. The first one insist the single chain exchange dominantly occurred in equilibrium state.40,41 
The second theory suggests the micelle fusion occurred in near equilibrium.42 As the drug release 
mechanism is related to micelle disruption, the trials for basic understanding of micelle forming 
kinetics are worthwhile research.  
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2.2 Research Objectives 
 
The endeavor to make a perfect system by development of polymeric micelle will not be useful 
without understanding of cargo release mechanism. There were bunch of researches regarding 
polymeric micelle system. However, most of the researchers kept the investigation of the fundamental 
principle for drug release problem as unclear. In this study, we concentrated on to demonstrate the 
mechanism of cargo release from polymeric micelles.  
At first, we prepared numerous block copolymer candidates. They have a variety length of 
hydrophilic Poly (ethylene oxide) part or hydrophobic PLA part. After that, we prepared micelle 
system using DiI and DiO as model drug. Finally, we examine the Fluorescence resonance energy 
transfer (FRET) ratio depend on each polymeric micelle system and try to find out the tendency of 
drug release. Considering the effect of the complementary system in vivo, we optimized the condition 
for FRET experiment by adjusting the temperature or using a buffer solution for the complementary 
system in the biological environment. 
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Figure 2.1 Schematic representation of demonstrating cargo release mechanism from polymeric 
micelle systems 
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2.3 Materials and Methods   
 
General 
 
Poly(ethylene glycol) methyl ether (mPEG-OH) (average Mn 5000, 10,000, and 20,000), 3,3′-
Dioctadecyloxacarbocyanine perchlorate (DiO), 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-
indocarbocyanine perchlorate (DiI)  and Tin(II) 2-ethylhexanoate were purchased from Sigma 
Aldrich. DL-Lactide was obtained from TCI. Dynamic light scattering (DLS) measurement was 
performed using Malvern Nanozetasizer. Proton nuclear magnetic resonance (Proton NMR, δH) were 
recorded by using an Agilent 400-MR DD2 spectrometer. The fluorescence spectra were measured by 
Agilent Cary Eclipse. Molecular weights of the polymers were estimated by Gel permeation 
chromatography (GPC) with a refractive index detector 
 
Synthesis of PEO-b-PLA 
 
We chose PEO-b-PLA as model drug carrier to investigate cargo release. PEO-b-PLA is 
amphiphilic copolymers that form core-shell structured micelle from self-assembly. Their hydrophilic 
Poly ethylene oxide (PEO) part was used for a long time because of their prolonged circulation time 
in vivo as well as improved aqueous solubility. Furthermore, hydrophobic PLA part is generally used 
for biocompatibility, simple clearance and drug release control. We prepared variety of PEO-b-PLA 
candidates using ring-opening polymerization. PEO part was chemical reagent itself which was 
purchased from the commercial source. Length of hydrophobic PLA was adjusted by different 
equivalent of DL-lactide at the synthesis step. Total 11 different kinds of PEO-b-PLA were 
synthesized. Composition of PEO and PLA was identified 1H NMR spectroscopy and GPC. Exact 
molecular weight was calculated based on 1H NMR result. GPC was used for checking the increase of 
molecular weight by comparing with starting material. Polymer 1 to 5 were synthesized from PEO 
5000, polymer 6 to 9 were started from PEO 10000. Polymer 10 and 11 include PEO 20000 as 
hydrophilic part (Table 2.1). 
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Figure 2.2 Synthetic scheme of PEO-b-PLA 
 
 
Synthesis of polymer 5K-4K 
mPEG-OH(Mn 5000) (1 g, 0.2 mmol) and DL-Lactide (1.297 g, 9 mmol) were contained in 2-neck 
round bottom flask at 90℃ under Ar purging. After the reagents melt from heat, 5 mL of toluene was 
added to the reaction vessel. The reaction mixture kept 10 min under reflux condition to give well-
dissolved solution. Finally, Tin(II) 2-ethylhexanoate (0.05 mL) was added as dropwise to the mixture.  
The reaction was performed during 1 day to obtain white-colored solution. After reaction, the reaction 
mixture was dissolved in Dichloromethane (DCM) to purification against hexane. Precipitation 
performed twice to obtain pure powder. However, because of poor solubility of PLA in hexane, 
further separation step using Gel permeation chromatography was performed. After purification, the 
compound was identified by proton NMR.  
 
Synthesis of polymer 5K-7K  
All polymers were prepared through same procedure. The equivalent was the only variation for 
these polymer series. The reaction was performed using mPEG-OH(Mn 5000) (1 g, 0.2 mmol) and 
DL-Lactide (1.7295 g, 12 mmol).  
 
  Synthesis of polymer 5K-8K   
The polymer 5K-8K was originated from polymer 5K-7K. The polymer was separated from GPC 
by following different molecular weight distribution. The details of synthetic procedure are same as 
the synthetic method of polymer 5K-4K. 
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Synthesis of polymer 5K-14K  
mPEG-OH(Mn 5000) (1 g, 0.2 mmol) and DL-Lactide (4.3239 g, 30 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K. 
 
Synthesis of polymer 5K-28K  
mPEG-OH(Mn 5000) (1 g, 0.2 mmol) and DL-Lactide (7.2065 g, 50 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K. 
 
Synthesis of polymer 10K-5K 
mPEG-OH(Mn 10000) (0.5 g, 0.05 mmol) and DL-Lactide (6.485 g, 45 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K. 
 
Synthesis of polymer 10K-7K  
mPEG-OH(Mn 10000) (0.5 g, 0.05 mmol) and DL-Lactide (0.7237 g, 5 mmol) were used for this 
reaction The details of synthetic procedure are same as the synthetic method of polymer 5K-4K.  
 
Synthesis of polymer 10K-16K  
mPEG-OH(Mn 10000) (1 g, 0.1 mmol) and DL-Lactide (2.882 g, 20 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K. 
 
Synthesis of polymer 10K-28K  
mPEG-OH(Mn 10000) (1 g, 0.1 mmol) and DL-Lactide (5.765 g, 40 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K. 
 
 
 
12 
 
Synthesis of polymer 20K-10K 
mPEG-OH(Mn 20000) (1 g, 0.05 mmol) and DL-Lactide (1.3692 g, 9.5 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K . 
 
Synthesis of polymer 20K-28K 
mPEG-OH(Mn 20000) (1 g, 0.05 mmol) and DL-Lactide (2.5943 g, 18 mmol) were used for this 
reaction. The details of synthetic procedure are same as the synthetic method of polymer 5K-4K.  
 
 
Polymeric Micelle Formation   
 
In this research, we used nanoprecipite method to form polymeric micelle. This method is based on 
self-assembly of block copolymers. Their different solubilities of two distinct chains enable to build 
core-shell like spherical micelles. The PEO-b-PLA polymers in nano-precipitation leads to 
nanoparticles that encapsulated hydrophobic drugs with maintain the stability by hydrophilic PEO 
shell. The preparation procedure is shown in following paragraph. 
  100 uL of DiI or DIO as model drug (0.75 wt% of the polymer) was dissolved in the acetone. 400 
uL of polymer solution (25 mg/mL in acetone) was added to the dye solution and then stirred for 30 
min. The mixture of the organic solution was added to 5 mL of distilled water with 2 mL/min speed 
using syringe pump. The mixture was kept for 4 hours to evaporate acetone. After that, Dye-
encapsulated polymeric micelle solution was dialyzed against 2 liters of deionized water (Spectra/Por 
MWCO 3500) for 1 day.43 The average size of PEO-b-PLA micelles was measured by DLS at 25℃.  
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FRET Analysis   
 
We investigated the change of FRET ratio with time dependence. We made several assumptions 
regarding the tendency of FRET ratio. First, if cargo molecules depend on diffusing from the 
hydrophobic core, as hydrophilic shell thicker, the FRET ratio will be reduced. Second, if polymeric 
micelles exchange their cargo with hydrophobic core collision, as the core thickness thinner, the 
FRET ratio will be increased under the condition of same hydrophilic shell thickness. Lastly, if the 
micelle system releases their cargo as repeating disassemble and assemble like equilibrium state, 
FRET ratio of model systems will be almost similar. Otherwise, FRET ratio goes weaker with large 
micelle diameter.  
 
  For FRET experiment, the sample was prepared by following procedure. The 500uL of DiO 
contained polymeric micelle and 500 uL of DiI encapsulated polymeric micelle solutions were mixed 
to make total 1mL of micelle solution to measure their fluorescence. The intensity of the fluorescence 
signal was scanned from 494 nm to 800 nm with 484 nm of excitation wavelength. FRET ratio 
measurement was performed with time dependence. To make clear the tendency of each polymeric 
micelle system, FRET ratio IDiI/(IDiO+IDiI) was plotted against time.  
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2.4 Results and Discussion  
 
1H-NMR data of PEO-b-PLA 
 
The composition of PEO-b-PLA was calculated from proton NMR data. Based on these data, we 
named each polymer by ‘molecular weight of PEO part’-‘molecular weight of PLA part’. 
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Figure 2.3 1H-NMR spectra of polymer 5K-4K (400 MHz, CDCl3) δ : 1.53-1.59, 3.62-3.65, 5.13-
5.23. The molar ratio between two blocks was determined by integrating the polyethylene glycol unit 
and the proton in the poly(lactic acid) found to be 133: 54 The calculation based on proton NMR data 
gives the result as 3.89 kD of PLA was added to PEO(5 kD) units. 
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Figure 2.4 1H-NMR spectra of polymer 5K-7K (400 MHz, CDCl3) δ : 1.54-1.59, 3.63-3.65, 5.14-
5.23. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 133: 103. The calculation 
based on proton NMR data gives the result as 7.41 kD of PLA was added to PEO (5 kD) units. 
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Figure 2.5 1H-NMR spectra of polymer 5K-28K (400 MHz, CDCl3) δ : 1.48-1.58, 3.55-3.73, 5.11-
5.24. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 133: 389. The calculation 
based on proton NMR data gives the result as 28.05 kD of PLA was added to PEO (5 kD) units. 
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Figure 2.6 1H-NMR spectra of polymer 10K-5K (400 MHz, CDCl3) δ : 1.53-1.57, 3.63-3.64, 5.14-
5.23. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 227 : 74. The calculation 
based on proton NMR data gives the result as 5.33 kD of PLA was added to PEO (10 kD) units. 
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Figure 2.7 1H-NMR spectra of polymer 10K-7K (400 MHz, CDCl3) δ: 1.54-1.58, 3.63-3.74, 5.14-
5.23. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 227 : 91. The calculation 
based on proton NMR data gives the result as 6.55 kD of PLA was added to PEO (10 kD) units. 
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Figure 2.8 1H-NMR spectra of polymer 10K-28K (400 MHz, CDCl3) δ: 1.54-1.59, 3.64-3.65, 5.14-
5.23. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 214 : 395. The calculation 
based on proton NMR data gives the result as 28.44 kD of PLA was added to PEO (10 kD) units. 
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Figure 2.9 1H-NMR spectra of polymer 20K-10K (400 MHz, CDCl3) δ: 1.54-1.59, 3.59-3.69, 5.14-
5.23. The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 454 : 138. The calculation 
based on proton NMR data gives the result as 9.94 kD of PLA was added to PEO (20 kD) units. 
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Figure 2.10 1H-NMR spectra of polymer 20K-28K (400 MHz, CDCl3) δ: 1.52-1.59, 3.64, 5.14-5.23. 
The molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit and the proton in the poly(lactic acid) found to be 454 : 384. The calculation 
based on proton NMR data gives the result as 27.65 kD of PLA was added to PEO (20 kD) units. 
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GPC Results of PEO-b-PLA 
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(b) PEO 10K series 
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(c) PEO 20K series 
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Figure 2.11 GPC result of polymer series. (a) PEO 5K based polymers; (b) PEO 10K based polymers; 
(c) PEO 20K based polymers.  
 
Determination of increased molecular weight was based from the result of GPC. The standard of 
polymer was PEO as macro initiator which comes from commercial source. From the result, shorten 
retention time indicates increased of PLA part. In the figure 2.11c, peak of polymer 20K-28K is 
behind of the peak of 20K-10K. However, the retention time of 20K-28K more shorten than that of 
20K-10K. The reason of this phenomenon is supposed to be caused by high polydispersity of 20K-
28K. 
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Molecular Characteristics of the PEO-b-PLA Candidates 
 
Polymer 
Composition 
(EO : LA) 
Mn (Kg/mol) PDI ƒEO 
5K-4K 133:54 11.30 1.07 0.48 
5K-7K 133:103 12.54 1.18 0.43 
5K-28K 133:389 15.06 1.15 0.36 
10K-5K 227:74 16.85 1.06 0.78 
10K-7K 227:91 17.11 1.07 0.77 
10K-28K 227:395 28.02 1.24 0.47 
20K-10K 454:138 27.10 1.13 0.94 
20K-28K 454:384 33.26 1.10 0.77 
                                          *ƒEO =( Molecular weight of PEO part) / (Molecular weight of whole polymer.) 
 
Table 2.1 Characterization data of PEO-b-PLA candidates. The composition of polymer was based 
from 1H-NMR result ratio between repeating unit of PEO and repeating unit of PLA was described in 
this table. Average molecular weight (Mn), Polydispersity index (PDI) and ƒEO were calculated from 
GPC data.  
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Dynamic Light Scattering Results of Polymeric Micelle Systems  
 
(a)                                        (b) 
 
 
 
 
 
 
 
(c)                                        (d) 
 
 
 
 
 
 
 
 
 
(e)                                       (f) 
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(g)                                       (h) 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Size distribution data for polymeric micelle. Total concentration of each polymer solution 
was same as 2 mg/mL in DI water. (a) 5K-4K; (b) 5K-7K; (c) 5K-8K; (d) 5K-14K; (e) 5K-28K; (f) 
10K-5K; (g) 10K-7K; (h) 10K-16K; (i) 10K-28K; (j) 20K-10K; (k) 20K-28K 
 
  The polymeric micelle system was identified by size distribution data. Average diameter of these 
systems was within 100nm, which indicates that the size of these systems are applicable for in vivo. 
The single peak shape of every data indicates that every polymer candidates form stable micelle 
system in DI water. After encapsulate dye molecules, the shape of peak was not changed drastically. 
In the 5K-4K and 5K-7K systems, the diameter of DiO-encapsulated micelle is smaller than that of 
control micelle. The result indicates these two systems are unstable than other systems.  
 
 
 
 
 
 
 
 
 
0.1 1 10 100 1000 10000
0
5
10
15
20
 Polymer  20K-28K micelle
 20K-28K with 0.75wt% DiI
 20K-28K with 0.75wt% DiO
In
te
ns
ity
 (p
er
ce
nt
)
Diameter (nm)
0.1 1 10 100 1000 10000
0
5
10
15
20
 Polymer 20K-10K
 20K-10K with 0.75wt% DiI
 20K-10K with 0.75wt% DiO
In
te
ns
ity
 (p
er
ce
nt
)
Diameter (nm)
27 
 
Size Distribution Data of Micelle Systems from PEO-b-PLA Candidates 
 
Polymer 
Average hydrodynamic size (nm) 
Control With 0.75wt% DiI With 0.75 wt% DiO 
5K-4K 28.59 34.41 33.19 
5K-7K 38.72 39.01 38.59 
5K-28K 91.33 93.48 98.01 
10K-5K 35.11 39.36 38.34 
10K-7K 47.90 53.34 50.23 
10K-28K 86.41 94.18 99.19 
20K-10K 63.12 63.84 69.87 
20K-28K 88.94 89.10 93.23 
 
Table 2.2 Size distribution data for polymeric micelle series.  
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Measurement for Time dependent FRET Evolution  
 
(a)                                        (b) 
 
 
 
 
 
 
 
(c)                                        (d) 
 
 
 
 
 
 
 
 
 
(e)                                       (f) 
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(g)                                       (h) 
 
 
 
 
 
 
 
 
 
Figure 2.13 Time dependent FRET evolutions. The excitation wavelength was 484nm for exciting 
DiO. (a) 5K-4K; (b) 5K-7K; (c) 5K-28K; (d) 10K-5K; (e) 10K-7K; (f) 10K-28K; (g) 20K-10K; (h) 
20K-28K 
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Plotting of FRET Ratio Calculation  
 
(a) PEO length fixation 
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(b) PEO and PLA ratio fixation 
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(c) PLA length fixation 
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Figure 2.14 Results of FRET Ratio Calculation. (a) PLA length dependence; (b) PEO length 
dependence and (c) Whole length dependence.  
 
The polymeric micelle system was sorted by several standards. In the PEO length fixation, both 
PEO 5K and PEO 10K system showed PLA length dependence. As the length of PLA increases, the 
FRET ration was decreased. We supposed that the longer PLA chain cannot form stable hydrophobic 
core in the micelle system. However, the FRET ratio was not depends on length of PEO part. As 
shown in figure 2.14c and 2.14a, there are no trends with the change of hydrophilic PEO length. In 
case of PEO and PLA ratio fixation, the two polymeric micelle systems showed similar pattern.  
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2.5 Conclusion and Future Work  
 
We synthesized a variety of PEO-b-PLA series to investigate basic mechanism of cargo release. We 
choose this model drug carrier because of their biocompatibility, simple clearance, and easy 
preparation steps to micelle formation. We set the strategy with analysis of FRET result to 
demonstrate cargo release mechanism. Therefore, we investigated time-dependent FRET ratio change 
with their different PEO length, PLA length and the whole length with same PEO versus PLA ratio. 
By following current result, the polymeric micelle systems become unstable as hydorophobic core 
increases. However, there is no evidence of dye release regarding dependence of hydrophilic part. 
Keeping with the same ratio of hydrophobic part and hydrophilic can gives us the clue of effect of 
whole length dependence from the polymer. Current result showed the PEO 10K and PEO 20K show 
similar tendency up to 24hours. However, the result is not adequate for conclusion because of the 
small number of model system. The trend following whole length needed more investigation by 
introduce variety of micelle systems. The PLA length fixation was performed by fix the length of PLA 
part as 28K. However, the hydrophilic part of micelle system is 5K, 10K and 20K. That indicates the 
experiment performed with a micelle containing large hydrophobic core. For avoiding stability issues, 
we planned to further investigation by adjust PLA length which forms stable micelle system. 
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Chapter 3. Natural Polypeptide-Based Supramolecular Nanogels for Stable 
Noncovalent Encapsulation  
This chapter reproduced with permission of Ryu et al., Biomacromolecules, 2013, 14, 3515-3552  
Copyright 2013 American chemical Society 
Collaborations: All the biological analysis was done by Young Ji Kang (Prof. Sebyung Kang group) 
 
3.1 Introduction & Background 
 
Supramolecular Nanocarriers  
 
Nanogel is consisted of nanoscale polymer network. Especially, it has been applied in 
nanomedicine fields such as drug delivery and biomedical diagnostics.9 Their 10 to 200 nm size has 
advantage in targeting cancer for drug delivery due to their selectively accumulate in tumor tissues 
through enhanced permeation and retention effect.44,45,46 
Recent studies regarding drug carriers showed chemically cross-linked nanogel systems.47,48 The 
network prohibits simple diffusion of hydrophobic cargo molecules giving strong encapsulation 
ability. However, there are still weakness exist. First, the system is needed to be developed from 
chemical modification for cross-linkers. That will be the hurdle of general application because of their 
complex procedures. Second, the reaction regarding cross-linking is occurred from chemical reaction. 
There is the possibility to toxicity from the reaction between chemical reagents. This case needs 
additional purification step for biocompatibility with consuming preparation time.  
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3.2 Research Objectives 
 
We developed a simple method for synthesis of nanogels including high encapsulation stability. 
There are strong points of this system. First, the guest molecules can be easily sequestered within 
cargo molecules with high encapsulation stability. Secondly, tuning of the nanogel size is available by 
changing micelle-forming molecules. Third, the compatibility is obtained from corona composition 
with biodegradable natural polypeptide. Finally, noncovalently encapsulated cargoes can be released 
in response to biological stimulus using the matrixmetalloproteinase (MMP)), overexpressed at the 
edges of tumors.49,50,51 In this study, we demonstrated the encapsulation stability of nanogel without 
premature release. In addition to, the cargo release under high MMP concentration will be indicates 
that the emerging of smart targeting system for against to various solid tumors 
 
Figure 3.1 Schematic representation of supramolecular nanogel formation. The nanogels were 
prepared with two methods below and above critical micellar concentration (CMC) of surfactants and 
the chemical structures of positive surfactants. CTAB, cetyl trimethylammonium bromide; NG, 
nanogel; R4, hexadecane-RRRRG (R4); TAT, bis(hexadecane)-TAT. 
Method I
Below CMC
NG2: dense hydrophobic core
NG1: loose hydrophobic core
Self-assembly
N+
Br-
H
N
O
N
H
H
N N
H
H
N NH2
O
O
O
O
O
HN
H2N
HN
H2N
HN
H2N
HN
H2N
NH NH
NH NH
N
H
H
N N
H
H
N N
H
H
N N
H
H
N N
H
H
N NH2
NH
H2N NH
O
O
O
O
O
O
O
O
O
O
NH
HN NH2
NH
H2N NH
NH
H2N NH
NH
HN NH2
O
H2N
H2N
NH2
NH
H2N NH
H
N
O
NH
O
O
CTAB
R4
TAT
Supramolecular
amphiphiles
Method II
Above CMC
Gelatin polypeptide
35 
 
3.3 Materials and Methods     
 
General 
 
Gelatin type B from bovine skin (molecular weight = 40000−50000), cetyl trimethylammonium 
bromide (CTAB), succinic anhydride, palmitic acid, trifluoroacetic acid, thioanisole, 1,2-ethanedithiol, 
and 4-aminophenylmercuric acetate were purchased from Sigma Aldrich. Fmoc-protected amino acids 
and Rink amide MBHA resin were obtained from Anaspec. Fetal bovine serum (FBS) was from 
Gibco and Invitrogen. 3,3′-Dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1′-dioctadecyl-
3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate (DiI) as a lipophilic FRET pair were purchased 
from Invitrogen. MMP-9 was purchased from Abcam. Unless otherwise stated, all used materials 
were obtained from commercial suppliers (Sigma Aldrich, TCI, Anaspec, and EMD). Dynamic light 
scattering (DLS) measurements were made using a Malvern Nanozetasizer. The fluorescence spectra 
were obtained using a JASCO FP-6500 spectrofluorimeter. 
 
Gelatin Modification for High Negative Charge  
 
Gelatin type B (20 mg) was dissolved in 0.5 M NaHCO3 buffer (pH 9.2, 5 mL), and the solution 
was stirred at room temperature for 1 h. To this solution was slowly added succinic anhydride (100 
mg). After stirring overnight, the mixture was purified with Amicon Ultra (molecular weight cutoff = 
3000; Millipore; three times with distilled water). The final product was obtained as a white powder 
after lyophilization. Degree of modification was measured with the fluorescamine method 
 
Syntheses of Peptide Amphiphiles 
 
Peptides were synthesized on Rink amide MBHA resin via solid phase peptide synthesis using 
standard Fmoc methodology. Fmoc-L-lysine(Fmoc)−OH, in which both α- and ε-amines are protected 
with Fmoc, was then coupled for the dendritic growth of the peptide. Palmitic acid (Sigma Aldrich) 
was coupled manually after deprotection of the Fmoc group from the resin-bound peptide. Briefly, the 
coupling reaction was achieved with 3 equiv of Fmoc-protected amino acid, 3 equiv HBTU, and 3 
equiv DIPEA in dimethyl formamide (DMF) and monitored using the Kaiser test. The Fmoc 
protection group was removed using 20% piperidine in DMF. The resin was then washed with 
dichloromethane DCM (5×), DMF (5×), and tetrahydrofuran (5×) and dried in vacuo. The dried resin 
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was treated with a cleavage cocktail (trifluoroacetic acid/ethanedithiol/thioanisole, 95:2.5:2.5) for 3 h, 
and the cleavage mixture was precipitated in cold t-butyl methyl ether/hexane five times to afford the 
crude peptide. Crude peptides were purified with highperformance liquid chromatography with an 
acetonitrile and water mixture with 0.1% trifluoroacetic acid. Peptides were characterized with mass 
spectrometry 
 
Nanogel Preparation  
 
Method I (NG1). The measured amount of surfactant below the CMC was mixed with negatively 
charged gelatin type B to make supramolecular nanogels. The weight ratio between the surfactant and 
the gelatin was 1:8. For the CTAB-based nanogel (NG1-CTAB), 2.25 mL of CTAB (550 μM, below 
the CMC) as a positively charged surfactant was added dropwise to 250 μL of gelatin type B (20 
mg/mL) as a negatively charged polymer. To 1 mL of this nanogel solution (2 mg/mL of gelatin B) 
was added 5 μL of hydrophobic dyes (DiI or DiO) in acetone (1 mg/mL), and the mixture was stirred 
for 4 h at room temperature and opened to the atmosphere to allow the organic solvent to evaporate. 
Insoluble DiI/DiO was removed via filtration. Other nanogels (NG1-hexadecane-RRRRG [NG1-R4], 
NG1-bis(hexadecane)-TAT [NG1-TAT]) with different surfactants were prepared using the same 
procedure.  
 
Method II (NG2). The measured amount of surfactant above the CMC was mixed with negatively 
charged gelatin type B or modified gelatin B with succinic anhydride to make nanogels. The ratio 
between the surfactant and the gelatin was 1:8. For CTAB-based nanogels (NG2-CTAB), 36 μL of 
hydrophobic dyes (DiI or DiO) in acetone (1mg/mL) was added to 1 mL of CTAB (10 mM, above the 
CMC) micellar solution to be encapsulated. The mixture was stirred for 4 h at room temperature and 
opened to the atmosphere to allow the organic solvent to evaporate. Insoluble DiI/DiO was removed 
via filtration. To 200 μL of this CTAB micellar solution (10 mM) was added 250 μL of negatively 
charged gelatin type B (20 mg/mL), which was then mixed and diluted with 2.05 mL of distilled water 
to a final concentration of 2 mg/mL of gelatin B. Other nanogels (NG2-R4, NG2-TAT) with different 
surfactants were prepared using the same procedure. Highly negatively charged gelatin B modified 
with succinic anhydride was used to make more stable nanogels (NG2-CTAB-Suc) with the same 
procedure. For doxorubicin-containing nanogels, we used doxorubicin in CH2Cl2 (10 wt % compared 
to CTAB) instead of hydrophobic dye molecules. 
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Fluorescence Resonance Energy Transfer (FRET) Encapsulation Stability Experiment  
 
A nanogel solution containing DiI (100 μL) was mixed in a cuvette with a nanogel solution 
containing DiO (100 μL), and then Milli-Q water (800 μL) was added to adjust the volume. The 
fluorescence intensity was recorded at an excitation wavelength of 450 nm. 
 
Cell Culture 
 
The cell viabilities of the nanogels were tested with HeLa cells. The cells were cultured in T75 cell 
culture flasks using Dulbecco’s modified Eagle medium/nutrient mixture F-12 with a 10% FBS 
supplement. The cells were seeded at 10000 cells/200 μL in each well of a 96-well plate and allowed 
to grow for 24 h under incubation at 37 °C and 5% CO2. The cells were then treated with nanogels of 
various concentration and incubated for an additional 24 h. Cell viability was measured using the 
MTT assay, with each data point measured in triplicate. Fluorescence measurements were made using 
the plate reader SpectraMax M5 by setting the excitation wavelength at 560 nm and monitoring 
emission at 590 nm on a black well plate.  
 
3.4 Results and Discussion  
 
Design and Preparation of Supramolecular Nanogels 
 
We made supramolecular nanogels through electrostatic interaction between negative natural 
polypeptide (gelatin B) and a positive small surfact (CTAB and synthetic peptide amphiphiles). We 
investigated the formation of supramolecular nanogel through two approaches (Figure 3.1). The 
concentration of surfactant was the factor that makes two strategies different.  
The nanogel from method I was formed below the CMC of the positive surfactants. Each surfactant 
molecules interact with the polymer including negative charge. This interaction eventually forms 
nanoaggregation through hydrophilic-lipophilic balance. In case of method II, the supramolecular 
nanogel was prepared above CMC of the positive surfactants. The surfactant forms micelle first with 
the positive charge surface and then interacts with negative natural polymers resulting in core-shell-
like aggregations. In this point, we hypothesized that this tactics provides nanogel with high 
encapsulation stability. It is because of that the polymers would wrap the micelles and then prevent 
the simple diffusion of hydrophobic guest molecules from inside of nanogels.  
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  We used three cationic surfactants, CTAP (CMC = ~1mM), synthetic peptide amphiphiles 
including arginine-rich heads and hydrophobic hexadecane chains, R4 and TAT (Figure 3.1). The 
peptide emphiphiles were synthesized by Fmoc-peptide synthetic method and then purified with high-
performace liquid chromatography. Characterization was performed using matrix-assisted laser 
desorption/ionizationtime- of-flight mass spectroscopy   
The CMCs of surfactants were estimated from spectroscopic analysis. Nile red was used as model 
drug, which is insoluble in water without sequestered in hydrophobic core of micelle. We find the 
CMCs using various concentrations of the amphiphilic peptides R4 and TAT. The results of those 
were approximately 180 and 230 uM. 
The size distribution of supramolecular nanogels was measured by DLS. In water, three cationic 
surfactants showed assembly. In case of CTAB, the diameter of assembled micelle was 2.0 nm. R4 
and TAT showed 8.2 and 9.1 nm of hydrodynamic diameter. As shown in Table 1, size of the 
surfactants make increased size of the micelles. In case of complexes of gelatin polymer and cationic 
micelle showed larger size. From the results, the size of nanogel was controllable by following 
properties of different surfactants. 
 
 
 
 
 CTAB R4 TAT 
Surfactanta 2.0 ± 0.4 8.2 ± 0.3 9.1 ± 0.3 
NG1 typeb 3.6 ± 0.3 10.8 ± 0.7 6.9 ± 0.4 
NG2 typec 4.7 ± 0.6 17.5 ± 0.8 23.3 ± 0.8 
 
 
Table 3.1 Diameter of Surfactant Micelles and Supramolecular Nanogels 
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Figure 3.2. Size distribution of supramolecular nanogels. (a) prepared using method I (b) prepared 
using method.  
 
Encapsulation Stability 
 
The encapsulation stability of nanocarriers is important for preventing premature release before 
reaching the target site. The encapsulate stability was demonstrated from FRET-based method. At 
first, two FRET pair dye molecules, DiO and DiI (FRET donor and acceptor) were encapsulated 
independently in the supramolecular nanogels. The change of FRET ration was investigated by 
mixing two nangel solutions. The result was corresponded to our expectation by showing the sudden 
FRET evolution in case of using CTAB as the surfactant micelle with poor encapsulation stability. 
(Figure 3.3a).  
In case of NG1-CTAB prepared from method I showed immediately FRET evolution within 10 min. 
Furthermore, this system showed maintained emission intensity. (Figure 3.3b). From the result, we 
supposed that the dye exchange was occurred right after the mixing two solutions. By contrast, NG2-
CTAB using method II showed no significant change. This result indicates that the system have high 
encapsulation stability.  
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Figure 3.3 FRET evolutions from dye molecules. 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) 
and 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate (DiI) encapsulated within (a) 
CTAB micelles, (b) NG1-CTAB, and (c) NG2-CTAB. (d) Plot of FRET ratio vs. time. (e) Depiction 
of FRET study of supramolecular nanogels. 
 
41 
 
Nanogel Stability in Serum 
 
Because of that the assembly of our nanogel systems is based on electrostatic interaction, there is 
weak point of this strategy. In the serum, bunch of proteins of complementary systems have negative 
charge. That gives the possibility of the proteins can weaken our nanogel system from complexation 
through competitive electrostatic interaction. To investigate this problem, further FRET experiments 
were performed in the 10% FBS solution. NG2-CTAB, which showed high encapsulation stability 
was used for this study. (Figure 3.4a) In the result, the intensity of emission signal was gradually 
decreased with the time. That indicates that the electrostatic interaction between negative gelatin 
polymer and positive surfactant micelles can be weakened by serum proteins from competitive 
interaction causing disassembly of the nanogel system.  
We made one hypothesis regarding charge of interaction. The strength between core and shell can 
be affect by strength of electrostatic interaction of nanogel components. Based on this hypothesis, we 
modified gelatin B with succinic anhydride to obtain more negative charged one. The amine groups at 
the side chain of gelatin B enable to increasing of negative charge as change of positive amine to 
negative carboxylic acids. As shown in Figure 3.4b, the modified gelatin makes strong interaction 
with positive micelles giving highly stable supramolecular nanogels. In the DLS result, NG2-
CTABSuc model showed much larger hydrodynamic radius (14.7 nm) than NG2-CTAB, 4.7 nm. The 
increased nanogel size indicates more micelles can be encapsulated in this model. Their stability was 
investigated by diluted condition. The FRET ratio of NG2-CTAB was not changed up to 300 uM. In 
contrast, NG2-CTABsuc showed better stability by shown no change of FRET ratio even more diluted 
condition.  
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Figure 3.4.  Result of size distribution and FRET evolutions of NG2-CTAB system. (a) FRET 
evolutions within NG2-CTAB with 10% fetal bovine serum (FBS) in pH 7.4 
tris(hydroxymethyl)aminomethane (Tris) buffer solution. (b) Size distribution of nanogels. (c) FRET 
evolutions within NG2-CTAB-Suc at 10% FBS in pH 7.4 Tris buffer solution. (d) FRET ratio changes 
after dilution of nanogel solutions. 
 
 
 
 
 
 
 
 
 
 
43 
 
Triggered Hydrophobic Guest Release and Cell Viability 
 
The efficiency of drug nanocarriers for tumor has to include their triggered release from external 
stimulus regarding tumor microenvironments. In our nanogel system, MMP was the external stimuli 
for releasing cargos. Natural polypeptide components enable to this triggered release by degradation 
from MMP. To prove this system, we investigated the release of hydrophobic cargo from NG2-
CTAB-Suc with treat and without treat of MMP 9. (Figure3.5) The hydrophobic cargos were released 
up to 60% at 24h after treatment of MMP-9. However, in absence of MMP-9 showed no significant 
release by showing weaker emission signal from dilution.  
Cell viability assays were performed using HeLa cells. The nanogel system was treated with 
various concentrations to the cells with 24h incubation. MTT assay was used for measurement. This 
system showed high cell viability as well as no concentration-dependence up to 1 mg/mL of nanogel 
concentration. This result suggests that the nanogel have nontoxic property givin the possibility for 
biological applications.  
In vitro cell viability was performed with SCC-7 cells. SCC-7 is well known to be overexpress of 
MMPs. At first, we encapsulate doxorubicin as a cargo drug into supramolecular nanogels and then 
measured cell viability with MMPs activity. As shown in Figure 3.5e, Doxorubicin-contained nanogel 
system showed no toxicity. The result indicates that the MMPs make degradation of gelatin to trigger 
disassembly of our nanogel systems giving drug release. By comparing with free Dox molecule, Dox-
containing nangel system showed less toxicity from slow cargo release. The difference of toxicity 
from addition of MMP inhibitor showed that the supramolecular nanogel system have sensitivity to 
MMPs.  
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Figure 3.5 Triggered release data of NG2-CTAB-Suc system. Dye release from NG2-CTAB-Suc 
(0.65 mg/mL) at various times after incubation (a) with and (b) without active matrix 
metalloproteinase-9 (MMP-9). (c) Depiction of MMP-9-triggered disassembly of supramolecular 
nanogels. (d) In vitro toxicity of empty nanogels (NG2-CTAB-Suc) with HeLa cells; (e) Dox-loaded 
nanogels (NG2-CTAB-Suc) with SCC-7 cells in the absence/presence of MMPs inhibitor.     
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3.5 Conclusions  
 
We developed supramolecular nanogels with high encapsulation stability from simple preparation 
methods. Negative gelatin was performed the role as binding surfactant micelle with electrostatic 
interaction. The properties of gelatin B include biocompatibility, enzyme responsibility, and abundant 
in nature. We used two methods for preparation. Those are above CMC and below CMC. In case of 
above CMC showed high encapsulation stability different from the case of above CMC. The size of 
our nanogel system can be controlled by the size of surfactant micelles. In addition to, the degree of 
negatively charge modification of natural peptide showed enhanced electrostatic interaction with 
positive micelles. Noncovalently encapsulated hydrophobic dye molecule showed triggered release 
from MMP, which are highly overexpressed in edge of solid tumors. Furthermore, the supramolecular 
nanogel system gives nontoxicity. Therefore, this nanogel system exhibits high encapsulation stability, 
tunable size control, and triggered release in tumor cell. We expected that the supramolecular nanogel 
system have great potential for drug delivery system.   
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Chapter 4.  Affinity Protein-Conjugated Nanogel System  
 
4.1 Introduction & Background 
 
Affinity Proteins for the Drug Delivery System 
 
 Antibody, it is used for life science fields as the most general affinity proteins. Most of them in 
biological application are IgG molecule. It is multi-domain protein as a large molecule, depending on 
disulfide bonds to make complex. Even though they have great potential to application, there are 
vulnerable points regarding their intrinsic properties. First, they have reduced stability to against 
increased temperature. Secondly, difficult and complex manufacturing process is another hurdle. 
Finally, they only use a small part of it for antigen recognition.51  
  To avoid this weakness, numerous techniques using non-antibody molecule were developed. 
Affinity proteins, as a small single-domain protein, have durability to high temperature, and harsh 
chemical environment. Especially, their high selectivity and binding ability with the specific molecule 
have potential to be an attractive tool for biological application. There are several researches 
regarding development of affinity proteins as targeting probe in vitro and in vivo diagnostics already.          
Affibody was initially derived from staphylococcal protein A.52 The immunoglobulin region, 
domain-B has a unique property as affinity protein. The B-domain is consisted short cysteine free 
peptides with 58 amino acids. That can be folded into three-helical structure performing folding 
reaction.53 The mutated one from B-domain as specific purpose for increased chemical stability is the 
Z-domain that is used in this research.54  
Z-domain possessed Fc part of the antibody which including high affinity. In addition to, reduced 
affinity with Fab region provides flexible binding with various molecules. Their capability for 
specificity and diversity of binding is a key point for further application.55 Furthermore, they have 
productivity by using chemical peptide synthesis.56 
In therapeutic field, introduce affinity protein to nanoparticle can be the efficient way to cure 
diseases. In the designed system, affinity protein provides specific recognition to target cells. In 
addition to, the nanoparticle provides more impact by delivering numerous drug molecules. From this 
approach, the improved specificity and increased amount of drug molecules provide the impact 
method in the research of drug delivery system.  
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4.2 Research Objectives  
 
In this research, we introduce Glutathione-s-transferase-Z (GST-Z) domain in drug delivery system. 
The structure of GST-Z is consisted Z domain that include Glutathione-s-transferase(GST) by genetic 
modification. With their hexahistidine tags, GST-Z domain enables to produce proteins very easily. 
Furthermore, the ability of specific binding with various IgG has potential with broad application.  
Our self-cross linked polymeric nanogel from previous research was introduced as the delivery 
carrier. Pyridyldisulfide (PDS) units in the random copolymer enable to make disulfide group through 
thiol exchange reaction with the cysteine in the Z-domain. The degree of ligand conjugation was 
measured through UV spectroscopy. The specificity of Fc region in the GST-Z domain as confirmed 
by the quartz crystal microbalance (QCM), surface plasmon resonance (SPR) and in vitro confocal 
imaging. The stability of nanogel carrier was checked the release of cargo molecule by a fluorometer. 
We used glutathione (GSH), a redox trigger, to cleave disulfide bond of the cross-linked nanogel. In 
addition to, time-dependent cargo release ratio was calculated from this result.  
Through this research, we expect the development of novel customizing drug delivery carrier. 
Modifiable, but including high affinity of GST-Z domain gives possibility to targeting specific IgG 
domains. By changing target domain, we can make custom-specific ligand molecule. In case of 
nanogel, it has no limitation for encapsulation of hydrophobic cargo molecule. Furthermore, 
ingredients of this carrier have reproducibility to produce. Finally, simple conjugation step between 
ligand and drug carrier have a great advantage in the application. With simple methods, we can 
change ligand molecule as well as cargo inside of the polymeric system. From this research, we 
expect that emerging of patient-customized therapeutic agent.  
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Figure 4.1 Schematic representation of GST-Z-conjugated nanogel system.  
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4.3 Methods and Materials  
 
General 
 
2-cyano-2-propyl-benzodiothioate, Triethylamine and polyethylene glycol monomethyl ether 
methacrylate were obtained from Sigma Aldrich. Doxorubicin hydrochloride was purchased from 
commercial source. Azobisisobutyronitrile, pyridyl disulfide ethyl methacrylate were prepared using a 
previously reported procedure.49 Proton nuclear magnetic resonance (δH) were recorded by using an 
Agilent 400-MR DD2 spectrometer. The absorption spectra was obtained from a JASCO V-670 
spectrophotometer  
 
Synthesis of Self-Crosslinked Polymer  
 
The polymer nanogel is consisted of polyethyleneglycol (PEG) unit and pyridyldisulfide (PDS) 
groups.57,58 Polymers were synthesized from reversible addition-fragmentation chain transfer 
polymerization.46,59,60   
A mixture of 2-cyano-2-propyl-benzodiothioate, PDSEMA (1 g), polyethylene glycol monomethyl 
ether methacrylate (739 mg) and AIBN (12.38 mg) was dissolved in THF and degassed by Ar purging. 
The reaction mixture was stirred during 12h under 60℃. The mixture was purified with cold etherThe 
molar ratio between two block was determined by integrating the methoxy proton in polyethylene 
glycol unit and the aromatic proton in the pyridine and found be 67%:33% (PEO:PDSEMA) 
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Loading Degree of Doxorubicin (DOX)  
 
  Most of the researchers chose the nanoprecipitate method because of simple preparation steps and 
mild condition for the micelle formation. In this process, organic solvent is used for dissolving 
polymers and drug molecules. The mixed organic solvents are mixed as dropwise in an aqueous phase 
under stirring.61 When the organic phase contacts with the water, the hydrophobic components in the 
organic solutions are precipitated and then occurs self-assembly into core-shell like structure for 
reducing the free energy.62 After self-assembly, the organic solvent kept under atmospheric pressure 
for evaporation. In the middle of this nanoprecipitate method, the hydrophobic drug molecule is 
entrapped in the core of the nanoparticle, surrounded by hydrophilic PEGylated shell for stabilization 
in aqueous environment. 63 
In this research, Doxorubicin was used for hydrophobic drug. The amount of the drug molecule for 
encapsulation step was 8wt% of polymer. 100 equivalent of trimethylamine was used with the 
doxorubicin for efficient encapsulation. The loading degree of doxorubicin was calculated from UV 
spectroscopy. The details of calculation are described in following paragraph.  
8 wt% of Doxorubicin to weight of polymer was added into polymer solution (10 mg/mL) with 
triethylamine. Dialysis was performed to remove excess of drug molecule. The final loading amount 
was calculated based on molar extinction coefficient of DOX (115 ⅹ103 M-1 cm-1) at 480 nm. 
 
The polymer concentration: 1 mg/mL solution (diluted from 10 mg/mL stock from the nanogels used 
for UV measurement to 1 mg to final volume of 1 mL) 
 
NG DOX: Abosorbance at 480 nm = 0.521 
 
By Beer’s law [C] = 0.520581 𝑐𝑐 × 11500 1𝑀 × 𝑐𝑐 = 4.52678 × 10−5 
Conversion to grams of  DOX :  
[C] = 4.52678 × 10−5 𝑐𝑚𝑚
𝐿
× 543.52 𝑔
𝑐𝑚𝑚
= 0.02460 gL = 0.02460 𝑐𝑔/𝑐𝐿 
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Because of 10 times of dilution, the concentration of Doxorubicin in initial solution is 0.246 mg/mL. 
Therefore, 0.246010 × 100𝑤𝑤% = 2.460 𝑤𝑤% 
of DOX was loaded in the nanogel solution. (Figure 4.2) 
300 400 500 600 700 800
0
2
4
Ab
so
rb
an
ce
 (a
.u
.)
Wavelength (nm)
 10X Diluted DOX-NG
480nm, 0.52058
 
 
Figure 4.2 UV Absorbance of DOX-NG to calculate loading degree of doxorubicin. 
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Investigation of Stability Issues Regarding Reduced Environment  
 
To explore triggered release, we used GSH as the stimulus. GSH exists in the cytosol as millimolar 
concentrations throughout the body. The disulfide bonds in our nanogel system can be cleaved in 
presence of GSH. Therefore, a GSH triggered release can be efficient method for intracellular 
delivery.64 We prepared Doxorubicin encapsulated nanogel with treat of DTT for crosslinking. After 
that, we treated GSH solution to the Dox-NG with various concentrations to trace the degree of 
release cargo from Dox-NG system. The intensity of the excitation signal of doxorubicin (545 nm) 
was used for calculating relative release. (Figure 4.5) 
 
GST-Z Domain Conjugation 
 
GST-Z/Ab domain as targeting ligand was treated to DOX-NG through simple mixing method. The 
mechanism of ligand conjugation was thiol exchange reaction between the surface of nanogel and 
cysteine of ligand. The mixture was kept with stirring at room temperature during overnight. After the 
conjugation, unreacted GST-Z proteins were removed through ultrafiltration (MWCO: 100 kDa). The 
concentrated proteins were measured to find out the stoichiometry. Through this reaction, 
pyridothione group of surface of nanogel is cleaved. The degree of ligand conjugation was identified 
by UV spectroscopy by checking pyridothione peak in the filtrated solution. (Figure 4.7) 
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4.4 Results and Discussion  
 
Characterization Data of Self-Crosslinked Polymer  
 
The property of PEO group is well known for their biocompatibility. In this research, PEO 
introduced the charge-neutral functional group. As the lipophilic functional groups, the PDS performs 
several roles. First, it allows performing supramecular amphiphilic assembly in the aqueous solution. 
Secondly, because of the amphiphilic nature, PDS makes the liphophilic guest molecules entrapped 
within the nanoassembled structure before the crosslinking. Third, it possesses thiol group that 
enables to perform disulfide cross-linking in the mild condition. Finally, the disulfide groups in the 
cross-linkers can be cleaved through thiol-disulfide exchange reactions. . 1H NMR (400 MHz, CDCl3) 
δ : 8.45, 7.67, 7.10, 4.21, 4.07, 3.65, 3.63, 3.55, 3.54, 3.37, 3.02 . 
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Figure 4.3 NMR spectra of PEO:PDSEMA polymer 
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Triggered Cargo Release from Dox-NG  
 
 (a)                                       (b) 
 
 
 
 
 
(c)                                       (d) 
 
 
 
 
 
Figure 4.4 Time dependent triggered release of Dox-NG under treatment of GSH. (a) 0mM GSH 
treated ; (b) 1mM GSH treated; (c) 5mM GSH treated; (d) 10mM GSH treated 
 
The nanoparticle was shown triggered release in response to GSH. GSH, as the reductive reagent is 
abundant in cytosol. By following this result, the nanoparticle released their cargo under GSH 
condition. As the concentration of GSH increased, the degree of release also increased. The drug 
leakage was shown in case of 0 mM GSH treated sample. However, the level of release was less than 
5% after two days. (Figure 4.5) The result indicates the self-crosslinked nanogel system showed not 
that much significant leaking outside of cytosol. The drastic increasing of doxorubicin signal gives us 
the result of the nanogel system has ability to triggered release under reductive environment. 
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 Figure 4.5 Doxorubicin release profile from Dox-NG under GSH treatment 
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Size Distribution of GST-Z/Ab Domain 
 
The average size of the nanoparticle before GST-Z modification was 59.8nm. After GST-Z 
modification, the size of nanoparticle was increased up to 139.0 nm. The diameter of GST-Z modified 
nanogel was increased.  
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Figure 4.6 Size distribution data of Dox-NG and Dox-NG with GST-Z domain modification. The 
concentration of polymer solution was 1 mg/mL in DI water. 
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Conjugation of Ligand Molecule  
 
From the self-cross linked nanogel, we can identify the degree of crosslinking. That is the 
measurement of cleaved pyridothione from polymer nanogel. In this research, we checked the 
pyridothione peak in the UV to assign the ligand conjugation. After simple preparation for affibody-
conjugated nanoparticle, unreacted GST-Z domain was gathered through ultrafiltration. Different from 
nanogel system and ligand-conjugated nanogel system, the filtration gave us the result of pyridothione 
peak at 343nm region. By following this outcome, we supposed that the ligand conjugation was 
performed correctly.  
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Figure 4.7 UV absorbance data for identifying ligand conjugation with nanoparticle system.  
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Targeting Efficiency of GST-Z-Conjugated Nanoparticle 
 
The targeting efficiency of our nanoparticle system was investigated by Fluorescent microscopic 
imaging. Prof. Sebyung Kang group performed the research regarding cell viability and protein 
conjugation. The nanoparticle with ligand conjugation was treated to SKBR3, SCC-7 and KB cells. 
These three different cell lines come from breast cancer, squamous cell carcinoma, and 
nasopharyngeal carcinoma. Their specific protein can recognize each different cell line. As shown in 
Figure 4.8, Figure 4.9 and Figure 4.10, the degree of internalization was shown with higher signal of 
doxorubicin only in case of treating Dox-NG-GST-Z. Even though the intensity was not exactly same 
among three models, the better performance of internalization ability indicates that the nanogel 
system gets specific targeting effect through conjugation with affinity protein.  
 
 
Figure 4.8 Fluorescent microscopic images of SKBR3 cells treated with Dox-NG-GST_Z (A-C) and 
SKBR3 cells treated with Dox-NG-GST_Z /Ab (D-F). DAPI (left), fluorescein (middle) and merged 
(right) images were presented. The nuclei were visualized as blue 
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Figure 4.9 Fluorescent microscopic images of SCC-7 cells treated with Dox-NG-GST_Z (A-C) and 
SCC-7 cells treated with Dox-NG-GST_Z /Ab (D-F). DAPI (left), fluorescein (middle) and merged 
(right) images were presented. The nuclei were visualized as blue 
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Figure 4.10 Fluorescent microscopic images of KB cells treated with Dox-NG-GST_Z (A-C) and KB 
cells treated with dox NG-GST_Z /Ab (D-F). DAPI (left), fluorescein (middle) and merged (right) 
images were presented. The nuclei were visualized as blue 
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4.5 Conclusions  
 
We developed novel nanocarriers with high targeting ability. Affinity proteins have special 
selectivity to target molecule. We introduce the GST-Z proteins as antibody binding domain to our 
nanogel system. We expected that the GST-Z domains can be conjugated to the surface of cross-linked 
nanogel. The reason is that the surface of cross-linked nanogel was consisted of Pyridyl disulfide 
group to be cleaved from thiol exchange reaction. Furthermore, the cysteine in the Z-domain makes 
this reaction under the contact with our nanogel system. For ligand modification, we use just simple 
mixing method in the mild condition. After modification, the nanogel system with GST-Z/Ab showed 
high performance for targeting effect by comparing control experiment. This special nanocarrier 
system from facile method can be applicable by their flexibility to change antibody molecule as well 
as low limitation to encapsulate cargo molecule. From this research, we expect the development of 
this model drug carrier can be the reproducible one to cure diverse disease through patient-
customizing.  
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Chapter 5. Mitochondria Targeting Nanogel System for Drug Delivery  
 
5.1 Introduction & Background 
 
Mitochondria Targeting Drug Delivery 
 
Mitochondria as organelle have an extraordinary ability regarding fate of the cell. They perform a 
critical role in cell living such as reproduce of ATP, defense of oxidative stress and induce apoptosis. 
Especially, mitochondria in cancer cell are shown abnormal development due to fast growth of tumor. 
For these reasons, it is worthwhile to concentrate on developing mitochondria-targeting system to 
overcome cancer. However, most of the researchers in drug delivery area are only focused on 
targeting cell internalization. Even though they deliver their drug to the cell successfully, the cargo of 
them is targeting nucleus to kill the cancer cell. Furthermore, as a drawback of chemotherapy, the 
rising problem for this Drug delivery system (DDS) regards multi-drug resistance. In the 
mitochondria, there is no efflux channel for the drug molecule. Because of this reason, if we target 
mitochondria directly, we can expect overcome multidrug resistance. Therefore, direct stimulate 
protein signaling system to induce apoptosis will be the powerful method than delivery bunch of drug 
molecules.  
Research area of targeting mitochondria has a short history, and there are few discoveries to 
application. Different as usual DDS, we can use just two kinds of ligand molecules to targeting 
mitochondria such as triphenyl phosphate cation and mitochondria penetrating peptide.65 As previous 
researches, conjugate these ligands with small drug molecule cannot show their efficiency because of 
the limitation of the ligand molecule itself. These two ligands have disadvantage that they cannot 
deliver high molecular weight of cargoes.31 In this point, drug delivery system with mitochondrial 
targeting molecule can be designed to jump over the cargo delivery problem. Furthermore, by 
introduce drug delivery system to mitochondrial targeting, we expect to get over renal clearance 
problem of small drug molecule. Therefore, targeting mitochondria is supposed to have efficiency for 
killing cancer cell. 
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Figure 5.2 Schematic representation of mitochondrial targeting drug delivery system 
  
Mitochondria specific drug  
Mitochondria targeting ligand 
Surface modification  
Shielding cationic charge  
Induce apoptosis  
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5.2 Research Objectives 
 
This research is concentrated on the delivering a mitochondria-targeting molecule through drug 
delivery system. For develop this new kind of delivery vehicle, we introduce mitochondrial targeting 
ligand molecule to self-crosslinked nanogel. It has pyridyldisulfide functional groups on the surface, 
facilitating ligand conjugation through thiol-exchange reaction as forming disulfide group.  
  The ligand molecule was composed of hydrophilic ethylene glycol part for biodegradability and 
flexibility in the biological environment. Each ends of the molecule have thiol group and triphenyl 
phosphate group. Triphenyl phosphate group, as they are well known, will perform targeting 
mitochondria. The cationic charge is reported that penetrate double membrane of mitochondria easily. 
In addition to, the other end of thiol group will react with drug carrier for surface modification. 
Our strategy for actualization of mitochondrial targeting nanoparticle is start from encapsulating 
model drug molecule with self-crosslinked nanogel. After that, thiolated mitochondrial targeting 
ligand molecule will be modified surface of nanogel through thiol exchange reaction.  
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5.3 Materials and Methods  
 
General 
 
Hexaethylene glycol was purchased from Alfa Aesar. potassium hydroxide(KOH), hydrochloric 
acid, potassium iodide(KI), sodium chloride, sodium bicarbonate and magnesium sulfate were 
obtained from Samchun chemical Co., Ltd. P-toluenesulfonyl chloride, Potassium thioacetate, Sodium 
methoxide were purchased from Sigma Aldrich, Glutatione (reduced form), triphenylphosphate was 
obtained from TCI.  
 
Synthesis of Mitochondrial Targeting Ligand Molecule 
 
We started from hexaethylene glycol for hydrophilic interaction for the intracellular environment. 
To facilitate SN2 reaction, the reaction for ditosylation was performed. After that, modification of each 
end of the lignad was performed through SN2 reaction with triphenylphosphate and thioester. 
Triphenylphosphate will be expected to have targeting effect to mitochondria. In addition to, thioester 
as precursor of thiol group will be help to generate thiol group. That thiol group will react with 
pyridyldisulfide group of nanogel. Hydrolysis with sodium methoxide was performed to make thiol 
substrated ligand molecule. Because of their unstability, the final reaction was performed every before 
of nanogel modifiacion. The degree of modification was checked through UV spectroscopy. Increased 
signal of pyridyl disulfide group indicates the thiol exchange reaction was performed between ligand 
molecule and nanogel surface.  
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Figure 5.2 Synthetic scheme of mitochondrial targeting ligand. (a) KOH, DCM, 0℃, 3h; (b) KI, 
Acetonitrile(ACN), 90℃, 24h; (c) Triphenylphosphate, ACN, 90℃, 24h; (d) Potassium thioacetate, 
DMF, 90℃, 24h; (e) Sodium methoxide, Methanol(MeOH), 6h 
 
 
Hexaethylene glycol di-p-toluenesulfonate 1  
 
Hexaethylene glycol (5 g, 17.7 mmol) was prepared in round bottom flask. The reaction vessel was 
installed in ice bath. DCM was added as solvent and then grinded potassium hydroxide (7.945 g, 
141.6 mmol) was added during stirring. Finally, p-toluenesulfonyl chloride (13.59 g, 141.6 mmol) 
was added to the reaction mixture. The mixture was stirred during 3 hours with high rpm. After the 
reaction, DW was added the reaction vessel to quench the reaction. pH adjusting was performed using 
Hydrochloric acid and Sodium bicarbonate and then organic phase was separated from the mixture 
with extraction (X3). The separated organic phase was washed with brine solution to remove salt 
molecules in the mixture. Finally, Magnesium sulfate was used for removing water. Filtration was 
performed after all procedure for removing salt.  
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17-iodo-3,6,9,12,15-pentaoxaheptadecyl hypoiodite 2 
 
  Hexaethylene glycol di-p-toluenesulfonate 1(1 g, 1.6929 mmol), Potassium Iodide (222 mg, 
0.8464 mmol) was added to reaction vessel. Acetonitrile was added to the reaction mixture and then 
sonication was performed to dissolve KI. The reaction was performed under 90℃ with reflux 
condition durgin 18 hours. After the reaction, the organic solvent was evaporated by rotary evaporator. 
Excess of iodine was removed by adding saturated sodium bisulfite solution. The filtered organic 
solvent was gathered and then identified by proton NMR  
 
(17-iodo-3,6,9,12,15-pentaoxaheptadecyl)triphenylphosphonium 3 
 
17-iodo-3,6,9,12,15-pentaoxaheptadecyl hypoiodite 2 (2 g, 3.98 mmol) and triphenylphosphate 
(1.04 g, 3.98 mmol) was added to round bottom flask. Acetonitrile was added as solvent to dissolve 
triphenylphosphate. The color of mixture was changed yellow to colorless. The reaction was 
performed under 90℃ with reflux condition with stirring during 18 hours. After the reaction, the 
organic solvent was evaporated by rotary evaporator. The compound was used for next reaction 
without identification because of their unstability.  
 
S-(17-iodo-3,6,9,12,15-pentaoxaheptadecyl) ethanethioate 4 
 
  (17-iodo-3,6,9,12,15-pentaoxaheptadecyl)triphenylphosphonium 3 (270 mg, 0.424 mmol) and 
potassium thioacetate (72.56 mg, 0.635 mmol) was added to DCM in the round bottom flask. The 
reaction was performed during 18 hours with stirring under 90 ℃. The crude was purified by column 
chromatography (Dichloromethane : Methanol = 20:1). Proton NMR was used for identification.  
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17-iodo-3,6,9,12,15-pentaoxaheptadecane-1-thiol 5 
 
S-(17-iodo-3,6,9,12,15-pentaoxaheptadecyl) ethanethioate 4 (5 mg, 0.012 mmol) and Sodium 
methoxide (10 mg, excess) was added in the methanol. The mixture kept stirring under room 
temperature during 6 hours. After the reaction, organic solvent was removed through rotary 
evaporator. The dried salt was discarded through centrifuge with DCM. The organic solvent was 
removed once again through evaporator and vacuum line. The dried compound was dissolved in DI 
water to treat nanogel conjugation. The identification of final compound was performed through 
proton NMR and mass spectroscopy.  
 
Encapsulation of Model Drug Molecule  
 
We used DiI and DiO as hydrophobic model drug molecule. Formation of nanoparticle was 
performed through simple precipitation method. The amount of dye molecules were 1wt% of polymer.  
In case of encapsulation of model drug, as well-known method, dye molecules were dissolved in the 
organic solvent and then dropped to hydrogel state polymer solution. Just mixing two different phase 
solutions were stirred for 4 hours under opened atmosphere to evaporate the organic solvent. To make 
stable nanogel, the dipyridyl disulfide modified nanogel surface was crosslinked with Dithiothreitol. 
The degree of encapsulation was checked by UV spectroscopy. The signal of pyridothione at 343 nm 
indicates that the cross-linking through DTT was performed at nanogel surface through thiol exchange 
reaction. Size of nanoparticle was identified through DLS.  
 
Surface Modification  
 
Thioacetate substituted ligand molecule was changed as thiol-modified one through hydrolysis. The 
influence of sodium methoxide to nanogel was reduced by removing sodium methoxide salt from the 
reaction mixture. The thiol-modified ligand was added to dye-encapsulated nanogel and then stirred 
during 12h for surface modification. The degree of surface modification was identified by UV 
spectroscopy. Increased pyridothione signal at 343 nm indicates that the ligand conjugation was 
performed through thiol exchange reaction.  
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Targeting Ability of Mitochondria Targeting Nanogel System  
 
The ability of mitochondria targeting was identified by confocal microscopy. 20uL of 50X diluted 
polymer solution (0.1 mg/mL) was treated to cell line and then incubated with 4h. The signal of DiO 
that encapsulated in nanogel carrier was compared with the signal of mitotracker. As shown in figure 
5.8, two signal of mitotracker and nanogel sample was overlapped. Their poor resolution will be 
improved by testing higher amount of nanogel sample with more concentrated solution 
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5.4 Result and Discussion  
  
Characterization Data of Proton NMR 
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Figure 5.3 1H-NMR spectra of Hexaethylene glycol di-p-toluenesulfonate 1 (400MHz, CDCl3) δ: 
2.44(6H), 3.56-3.67(20H), 3.14(4H), 7.31(4H), 7.79(4H) 
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Figure 5.4 1H-NMR spectra of 17-iodo-3,6,9,12,15-pentaoxaheptadecyl hypoiodite 2 (400MHz, 
CDCl3) δ: 3.22(4H), 3.64 (16H), 3.75 (4H) 
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Figure 5.5 1H-NMR spectra of S-(17-iodo-3,6,9,12,15-pentaoxaheptadecyl) ethanethioate 4 (400MHz, 
CDCl3) δ: 2.29(s, 3H), 3.03 (t,2H), 3.30(m,4H), 3.39 (m,2H) , 3.51-3.58 (m,12H), 3.70-3.75 (m,4H), 
7.73-7.87(m,15H) 
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Hydrolysis of Ligand Molecule  
 
Figure 5.6 1H NMR result regarding hydrolysis of S-(17-iodo-3,6,9,12,15-pentaoxaheptadecyl) 
ethanethioate 4. Sodium methoxide was treated for hydrolysis. The proton NMR spectra showed (a) 
0h; (b) 2h; (c) 4h; (d) 6h after hydrolysis. 
 
The degree of hydrolysis was checked from proton NMR. After treating sodium methoxide, the 
proton NMR was measured every 2 hours. The result indicates that the hydrolysis was performed after 
2 hours with no further change. Hydrolysis was identified of disappeared acetyl peak at δ 2.29. 
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UV absorbance Measurement for Degree of Surface Modification  
 
As shown in figure 5.7, crosslinking of nanogel and surface modification with thiol-modified 
targeting ligand was performed well. However, in case of (d), the sample didn’t show that increased 
pyridothione absorption by comparing after DTT treatment and after ligand conjugation. Because of 
higher cross-linking density, there is one possibility to showed lower ligand conjugation. The effect of 
treatment of DTT will be needed to further investigation  
 
(a) Nanogel solution                       (b) DiO encapsulated nanogel  
 
 
 
 
 
 
 
 
(c) DiI encapsulated nanogel                 (d) DiO&DiI encapsulated nanogel  
 
 
 
  
 
 
 
Figure 5.7 Absorption spectra of pyridothione in UV spectroscopy (a) nanogel solution as control 
experiment; (b) DiO-encapsulated nanogel solution; (c) DiI-encapsulated nanogel solution; (d) DiO 
and DiI encapsulated nanogel solution. The concentration of polymer in the solution was 0.1 mg/mL  
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Targeting Ability of TPP-Conjugated Nanoparticle System 
 
(a) DiI channel                            (b) Mitotracker channel  
  
(c) DIC image                              (d) Overlapped  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Confocal microscopy images of DiI containing nanogel to identifying mitochondria 
targeting. 20mol% of DTT treated nanogels were incubated with Hela cell during 4h as 20 ug/mL of 
concentration. (a) DiI encapsulated nanogel with mitochondria targeting ligand; (b) mitotracker signal; 
(c) DIC image; (d) Overlapped image of nanogel and mitotracker  
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5.5 Conclusions and Future Work 
 
In this research, we synthesize mitochondrial target ligand start from hexaethylene glycol. The 
ethylene glycol moiety was expected to show high flexibility with biocompatibility in the biological 
environment. Each end of ligand was modified with mitochondrial targeting functional group. The 
ligand molecule was assigned by proton NMR spectroscopy. The thiol group of the ligand molecule 
performed thiol exchange on the surface of self-crosslinked nanogel.       
Simple solvent displacement method was performed to encapsulate model drug molecule. 
Successful encapsulation in the self-crosslinked nanogel was identified through UV spectroscopy. In 
this system, DTT was treated for surface crosslinking. However, DiI and DiO co-encapsulated model 
showed poor surface modification degree with unknown reason. There are several hypotheses 
regarding this result. In this system, if DiO molecule was not encapsulated in the core of nanogel, but 
intercalate with polymer molecule makes inhibit to thiol-exchange reaction between surface of 
nanogel and targeting ligand molecule. The amount of DTT for cross-linking of nanogel also can be 
the other reason of this phenomenon. To make clear the reason of this result, further experiments 
regarding DTT concentration is planned to be performed. 
Finally, the ability of targeting mitochondria was investigated through confocal microscopy. The 
result indicates that the nanogel system has an effect on delivering their cargo to mitochondria. 
Through this result, we planned detail experiments to get more clear evidence by adjusting 
concentration of nanogel solution. Further investigation with drug molecule and targeting efficiency 
will be examined as future work with in vivo experiments.  
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